Skip to main content
Fig. 2 | World Journal of Surgical Oncology

Fig. 2

From: Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer

Fig. 2

Kaplan–Meier curves of overall survival (OS), time to progress (TTP), and hepatic metastasis-free survival (HMFS) between the high-titer anti-HBc group and low-titer anti-HBc group. The light blue and red area represent 95% confidence intervals of each group. Patients in the high-titer anti-HBc group had shorter OS, TTP, and HMFS than those in the low-titer anti-HBc group

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us